SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.46 USD
-1.15 (-2.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $41.45 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SWTX 41.46 -1.15(-2.70%)
Will SWTX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Other News for SWTX
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics announces Phase 2b ReNeu trial data for ASCO
SpringWorks Therapeutics price target raised by $2 at JPMorgan, here's why
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference